Navigation Links
Eureka Therapeutics raises $21 million in series c to expand cancer immunotherapy pipeline

Eureka Therapeutics, Inc. announced today that the Company has secured $21 million in a Series C Financing. The new funding will be used to expand the Company's cancer immunotherapy pipeline and advance its lead programs to clinical development. New investor Yuan Capital led the round, with participation from Majuven and all existing major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital.

Eureka is engaged in the discovery and development of fully-human antibodies engineered to mimic the functions of a T cell receptor, a key component of the immune system. These therapeutic antibodies are designed to recognize proteins residing inside of cancer cells, and mobilize a patient's immune system to recognize and kill the diseased cell.

"This new funding will allow us to expand and advance our drug pipeline, as well as explore the synergistic effects of our drug candidates with other immunotherapies and immune modulators," said Cheng Liu, PhD, President and CEO of Eureka Therapeutics. "This moves us closer to our goal of providing cancer patients with safer and more effective treatments through novel immunotherapies."

"We are pleased to have the continued confidence and support of our existing investors, and we welcome our new investors," added Dr. Liu.

Earlier this year, the Company announced a license agreement with Novartis for the development and commercialization of ESK1, a preclinical-stage monoclonal antibody for the treatment of leukemia and other cancers. The antibody, targeting the intracellular protein WT1, was developed under a collaborative effort between Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center.


Contact: Elisa Pan
Eureka Therapeutics, Inc.


Page: 1

Related biology news :

1. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
2. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
3. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
4. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
5. Industry group release testing recommendations for oligonucleotide-based therapeutics
6. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
9. Emerging class of therapeutics represents a coming wave for developers and manufacturers
10. Natura Therapeutics product shown to improve decision making skills in older adults
11. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
Post Your Comments:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/6/2017)... ... 06, 2017 , ... On Tuesday, October 24th, ABC² (Accelerate ... first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. ... open to the public, but registration is required. , WHAT: ABC² Brain ...
Breaking Biology Technology: